Carmignani Luca, Pastore Antonio Luigi, Picozzi Stefano Carlo Maria, Finkelberg Elisabetta, Ratti Dario, Vizziello Damiano, Schirinzi Maria Lucia, Saccà Antonino, Pisano Francesca, Maruccia Serena
Department of Urology, IRCCS Policlinico San Donato, Milan, Italy.
Urology Division, Department of Medico Surgical Sciences and Biotechnologies, Sapienza University of Rome, Faculty of Pharmacy and Medicine, Latina, Italy.
Urology. 2016 Jul;93:152-7. doi: 10.1016/j.urology.2016.02.015. Epub 2016 Mar 23.
To evaluate the functional and operative results of thulium laser enucleation of the prostate (ThuLEP) in patients with indwelling catheters for refractory urinary retention.
Patients with indwelling catheter, undergoing ThuLEP for benign prostate hyperplasia, were prospectively enrolled. Every episode of urinary retention was treated with urinary catheter positioning followed by at least 2 attempts of catheter removal. Patients were investigated with flowmetry and the self-administered International Prostate Symptom Score questionnaire at 30 and 90 days following ThuLEP.
Three hundred eighty-one patients underwent ThuLEP, and 99 of these had indwelling catheters, but only 93 (24%) were eligible according to the inclusion criteria. In 46 patients the bladder catheter was removed on the first postoperative day, in 31 patients on the second postoperative day, in 5 patients on the third postoperative day, in 6 patients on the fourth postoperative day, in 1 patient on the fifth postoperative day, and in 2 patients each on the sixth and seventh postoperative days. The average hospital stay was 2.3 (±1.7) days. No patients undergoing ThuLEP, at the 90-day follow-up, required further catheterization. Flowmetry showed significant improvement in all parameters, and the mean International Prostate Symptom Score dropped from 21.33 preoperatively to 3.2 (P = .004) at 90 days postoperatively.
This prospective study shows that ThuLEP is a safe and effective approach in refractory urinary retention patients. In our case series, no patients required postoperative intermittent catheterization. All functional outcomes investigated reported a statistical significant improvement.
评估铥激光前列腺剜除术(ThuLEP)治疗难治性尿潴留留置导尿管患者的功能及手术效果。
前瞻性纳入因良性前列腺增生行ThuLEP的留置导尿管患者。每次尿潴留发作时,先进行导尿管定位,然后至少尝试拔除导尿管2次。在ThuLEP术后30天和90天,对患者进行尿流率检查及自行填写国际前列腺症状评分问卷。
381例患者接受了ThuLEP,其中99例有留置导尿管,但根据纳入标准只有93例(24%)符合条件。46例患者在术后第1天拔除膀胱导尿管,31例在术后第2天,5例在术后第3天,6例在术后第4天,1例在术后第5天,2例分别在术后第6天和第7天。平均住院时间为2.3(±1.7)天。在90天随访时,接受ThuLEP的患者均无需再次导尿。尿流率检查显示所有参数均有显著改善,国际前列腺症状评分平均从术前的21.33降至术后90天的3.2(P = 0.004)。
这项前瞻性研究表明,ThuLEP是治疗难治性尿潴留患者的一种安全有效的方法。在我们的病例系列中,没有患者需要术后间歇性导尿。所有调查的功能结局均有统计学意义的改善。